Among patients with non-small cell lung cancer (NSCLC) fueled by
ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.
Previous studies of genetic
alterations in lymphoma and lung cancer have found that certain genetic mutations — specifically when part of a
gene breaks off and gets fused to another — can inappropriately switch on
ALK, driving cancer cells to grow and divide.